4,946 Shares in Johnson & Johnson $JNJ Acquired by Stonebridge Wealth Management LLC

Stonebridge Wealth Management LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, Holdings Channel.com reports. The fund bought 4,946 shares of the company’s stock, valued at approximately $756,000. Johnson & Johnson makes up 0.7% of Stonebridge Wealth Management LLC’s investment portfolio, making the stock its 25th largest holding.

Other hedge funds also recently modified their holdings of the company. Semmax Financial Advisors Inc. boosted its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $35,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $48,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of Johnson & Johnson by 66.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares during the period. Finally, Gladwyn Financial Advisors Inc. bought a new stake in Johnson & Johnson in the second quarter valued at about $71,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Guggenheim increased their price target on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $207.55.

Johnson & Johnson Stock Up 0.8%

Shares of Johnson & Johnson stock opened at $211.65 on Monday. The firm has a market cap of $509.93 billion, a PE ratio of 20.43, a P/E/G ratio of 2.36 and a beta of 0.36. The business’s 50 day simple moving average is $196.09 and its 200 day simple moving average is $177.42. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion during the quarter. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.